High-risk patients: modern treatment strategy

被引:0
|
作者
Nebieridze, D. V. [1 ]
Meliya, A. [2 ]
机构
[1] State Res Ctr Prevent Med, Moscow, Russia
[2] Cardiol Clin Guli, Tbilisi, Georgia
来源
关键词
High-risk patients; antihypertensive therapy; lipid-lowering therapy; anti-aggregant therapy; Aspirin (R) Cardio; DISEASE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review summarizes modern views on high-risk patients as atherosclerosis-free individuals. The importance of high-risk approach is explained by the fact that this group encompasses the majority of cardiac patients, as well as the majority of cardiovascular events. Therefore, early diagnostics and adequate management of high-risk patients could substantially reduce the incidence of cardiovascular events. The modern treatment strategy for high-risk patients requires pharmaceutical intervention, and has the same principles as the treatment of patients with diagnosed cardiovascular disease. Such components of pharmaceutical treatment as antihypertensive, lipid-lowering, and anti-aggregant therapy are discussed in detail.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 50 条
  • [31] Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
    Mora, Jaume
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (05) : 647 - 653
  • [32] MODERN ASPECTS OF PREGNANCY, LABOR AND DELIVERY SURVEILLANCE IN HIGH-RISK PATIENTS
    MEGLICMATOH, V
    ZDRAVSTVENI VESTNIK, 1991, 60 (12): : 499 - 501
  • [33] DIVERSIFICATION - HIGH-RISK GROWTH STRATEGY
    BORSCHBERG, E
    UNTERNEHMUNG-SCHWEIZERISCHE ZEITSCHRIFT FUR BETRIEBSWIRTSCHAFT, 1977, 31 (01): : 21 - 29
  • [34] A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma
    Espinoza, Andres F.
    Patel, Roma H.
    Patel, Kalyani R.
    Badachhape, Andrew A.
    Whitlock, Richard
    Srivastava, Rohit K.
    Govindu, Saiabhiroop R.
    Duong, Ashley
    Kona, Abhishek
    Kureti, Pavan
    Armbruster, Bryan
    Kats, Dina
    Srinivasan, Ramakrishnan R.
    Dobrolecki, Lacey E.
    Yu, Xinjian
    Panah, Mohammad J. Najaf
    Zorman, Barry
    Sarabia, Stephen F.
    Urbicain, Martin
    Major, Angela
    Bissig, Karl-Dimiter
    Keller, Charles
    Lewis, Michael T.
    Heczey, Andras
    Sumazin, Pavel
    Lopez-Terrada, Dolores H.
    Woodfield, Sarah E.
    Vasudevan, Sanjeev A.
    JOURNAL OF HEPATOLOGY, 2024, 80 (04) : 610 - 621
  • [35] A POST-DISCHARGE MANAGEMENT STRATEGY FOR HIGH-RISK CARDIAC PATIENTS
    WYNDHAM, CR
    BRICKELL, HJ
    DILLON, CC
    WINDUS, PS
    ALBRECHT, DE
    CIRCULATION, 1983, 68 (04) : 227 - 227
  • [36] Socioeconomic disparities in survival after high-risk neuroblastoma treatment with modern therapy
    Zheng, Daniel J.
    Li, Anran
    Ma, Clement
    Ribeiro, Karina B.
    Diller, Lisa
    Bona, Kira
    Marron, Jonathan M.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (10)
  • [37] Treatment of High-Risk Neuroblastoma
    Hizhnikov, A.
    Kazancev, A.
    Kerimov, P.
    Pimenov, R.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S447 - S447
  • [38] TREATMENT OF HIGH-RISK CHORIOCARCINOMA
    BAGSHAWE, KD
    JOURNAL OF REPRODUCTIVE MEDICINE, 1984, 29 (11) : 813 - 820
  • [39] Treatment of High-Risk Neuroblastoma
    Krystal, Julie
    Foster, Jennifer H.
    CHILDREN-BASEL, 2023, 10 (08):
  • [40] Treatment of High-Risk Neuroblastoma
    Sung, Kiwoong
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S3 - S3